Advertisement

Japanese Journal of Radiology

, Volume 37, Issue 2, pp 165–177 | Cite as

Imaging of renal cell carcinoma in patients with acquired cystic disease of the kidney: comparison 11C-choline and FDG PET/CT with dynamic contrast-enhanced CT

  • Kazuhiro KitajimaEmail author
  • Shingo Yamamoto
  • Yusuke Kawanaka
  • Takayuki Katsuura
  • Masahiro Fujita
  • Yukako Nakanishi
  • Yusuke Yamada
  • Takahiko Hashimoto
  • Toru Suzuki
  • Shuken Go
  • Akihiro Kanematsu
  • Michio Nojima
  • Koichiro Yamakado
Original Article

Abstract

Purpose

To evaluate renal cell carcinoma (RCC) findings in acquired cystic disease of the kidney (ACDK) shown by 11C-choline and FDG PET/CT, and contrast-enhanced CT.

Materials and methods

Six ACDK patients with 7 RCCs underwent 11C-choline and FDG PET/CT, and contrast-enhanced CT before nephrectomy. Findings obtained with 3 imagings were evaluated and sensitivity detecting RCC was compared using 3-point grading scale (negative, equivocal, positive). The equivocal scale used for SUVmax ranged from 2.0 to 3.0 for PET/CT and a peak enhancement value ranging from 20 to 30 HU was used for CT.

Result

The histopathologic subtypes of 7 RCCs were clear-cell (n = 4) and ACD-associated RCC (n = 3). The negative/equivocal/positive grading results were 0/0/7 for 11C-choline-PET/CT, 0/3/4 for FDG-PET/CT, and 2/2/3 for CT. Three equivocal cases by FDG-PET/CT were 2 clear-cell RCCs and 1 ACD-associated RCC. CT of 3 ACD-associated RCCs showed negativity for 2 and equivocality for 1. Sensitivity defining equivocal interpretation as negative for 11C-choline-PET/CT, FDG-PET/CT, and CT was 100% (7/7), 57.1% (4/7), and 42.9% (3/7).

Conclusion

11C-choline-PET/CT was more sensitive to detect RCC in ACDK as compared to FDG-PET/CT and contrast-enhanced CT in our series. FDG-PET/CT may be limited for detecting clear-cell RCC, while CT may have difficulty with detection of ACD-associated RCC.

Keywords

Renal cell carcinoma (RCC) Acquired cystic disease of the kidney (ACDK) Choline Fluorodeoxyglucose (FDG) Positron emission tomography/computed tomography (PET/CT) 

Notes

Compliance with ethical standards

Ethical approval

We clearly state that human participants have the approval of an appropriate named ethics committee including Helsinki declaration.

Conflict of interest

We declare no financial support or relationship that may pose conflict of interest. The authors confirm that this manuscript has not been published or presented elsewhere, in part or in entirety, and is not under consideration by any other journal. All authors have made substantial contributions to this work and have read and approved the final submitted version.

References

  1. 1.
    Ishikawa I. Uremic acquired renal cystic disease. Natural history and complications. Nephron. 1991;58:257–67.CrossRefGoogle Scholar
  2. 2.
    Farivar-Mohseni H, Perlmutter AE, Wilson S, Shingleton WB, Bigler SA, Fowler JE Jr. Renal cell carcinoma and end stage renal disease. J Urol. 2006;175:2018–20 (discussion 2021).CrossRefGoogle Scholar
  3. 3.
    Tickoo SK, dePeralta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol. 2006;30:141–53.CrossRefGoogle Scholar
  4. 4.
    Foshat M, Eyzaguirre E. Acquired cystic disease-associated renal cell carcinoma: review of pathogenesis, morphology, ancillary tests, and clinical features. Arch Pathol Lab Med. 2017;141:600–6.CrossRefGoogle Scholar
  5. 5.
    Heinz-Peer G, Maier A, Eibenberger K, Grabenwöger F, Kreuzer S, Ba-Ssalamah A, et al. Role of magnetic resonance imaging in renal transplant recipients with acquired cystic kidney disease. Urology. 1998;51:534–8.CrossRefGoogle Scholar
  6. 6.
    Levine E. Renal cell carcinoma in uremic acquired renal cystic disease: incidence, detection, and management. Urol Radiol. 1992;13:203–10.CrossRefGoogle Scholar
  7. 7.
    Gulanikar AC, Daily PP, Kilambi NK, Hamrick-Turner JE, Butkus DE. Prospective pretransplant ultrasound screening in 206 patients for acquired renal cysts and renal cell carcinoma. Transplantation. 1998;66:1669–72.CrossRefGoogle Scholar
  8. 8.
    Cho C, Friedland GW, Swenson RS. Acquired renal cystic disease and renal neoplasms in hemodialysis patients. Urol Radiol. 1984;6:153–7.CrossRefGoogle Scholar
  9. 9.
    Takebayashi S, Hidai H, Chiba T, Takagi H, Koike S, Matsubara S. Using helical CT to evaluate renal cell carcinoma in patients undergoing hemodialysis: value of early enhanced images. AJR Am J Roentgenol. 1999;172:429–33.CrossRefGoogle Scholar
  10. 10.
    Ferda J, Hora M, Hes O, Reischig T, Kreuzberg B, Mírka H, et al. Computed tomography of renal cell carcinoma in patients with terminal renal impairment. Eur J Radiol. 2007;63:295–301.CrossRefGoogle Scholar
  11. 11.
    Rofsky NM, Weinreb JC, Bosniak MA, Libes RB, Birnbaum BA. Renal lesion characterization with gadolinium-enhanced MR imaging: efficacy and safety in patients with renal insufficiency. Radiology. 1991;180:85–9.CrossRefGoogle Scholar
  12. 12.
    Akita H, Jinzaki M, Akita A, Mikami S, Oya M, Kuribayashi S. Renal cell carcinoma in patients with acquired cystic disease of the kidney: assessment using a combination of T2-weighted, diffusion-weighted, and chemical-shift MRI without the use of contrast material. J Magn Reson Imaging. 2014;39:924–30.CrossRefGoogle Scholar
  13. 13.
    Ishikawa I, Morita K, Hayama S, Nakazawa T, Araki I, Higashi K, et al. Imaging of acquired cystic disease-associated renal cell carcinoma by contrast-enhanced ultrasonography with perflubutane microbubbles and positron emission tomography-computed tomography. Clin Exp Nephrol. 2011;15:136–40.CrossRefGoogle Scholar
  14. 14.
    Nakanishi Y, Kitajima K, Yamada Y, Hashimoto T, Suzuki T, Go S, et al. Diagnostic performance of 11C-choline PET/CT and FDG PET/CT for staging and restaging of renal cell cancer. Ann Nucl Med. 2018.  https://doi.org/10.1007/s12149-018-1287-3 (Epub ahead of print).Google Scholar
  15. 15.
    Hara T, Yuasa M. Automated synthesis of [11C]choline, a positron-emitting tracer for tumor imaging. Appl Radiat Isot. 1999;50:531–3.CrossRefGoogle Scholar
  16. 16.
    Curry NS. Small renal masses (lesions smaller than 3 cm): imaging evaluation and management. AJR Am J Roentgenol. 1995;164:355–62.CrossRefGoogle Scholar
  17. 17.
    Kuo PH, Kanal E, Abu-Alfa AK, Cowper SE. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology. 2007;242:647–9.CrossRefGoogle Scholar
  18. 18.
    Kitajima K, Yamamoto S, Fukushima K, Minamimoto R, Kamai T, Jadvar H. Update on advances in molecular PET in urological oncology. Jpn J Radiol. 2016;34:470–85.CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Middendorp M, Maute L, Sauter B, Vogl TJ, Grünwald F. Initial experience with 18F-fluoroethylcholine PET/CT in staging and monitoring therapy response of advanced renal cell carcinoma. Ann Nucl Med. 2010;24:441–6.CrossRefGoogle Scholar
  20. 20.
    Kitajima K, Fukushima K, Yamamoto S, Kato T, Odawara S, Takaki H, et al. 11C-Choline positive but 18F-FDG negative pancreatic metastasis from renal cell carcinoma on PET. Nagoya J Med Sci. 2017;79:273–7.PubMedCentralGoogle Scholar

Copyright information

© Japan Radiological Society 2018

Authors and Affiliations

  • Kazuhiro Kitajima
    • 1
    Email author
  • Shingo Yamamoto
    • 2
  • Yusuke Kawanaka
    • 3
  • Takayuki Katsuura
    • 1
  • Masahiro Fujita
    • 1
  • Yukako Nakanishi
    • 2
  • Yusuke Yamada
    • 2
  • Takahiko Hashimoto
    • 2
  • Toru Suzuki
    • 2
  • Shuken Go
    • 2
  • Akihiro Kanematsu
    • 2
  • Michio Nojima
    • 2
  • Koichiro Yamakado
    • 3
  1. 1.Division of Nuclear Medicine, Department of Radiology, PET CenterHyogo College of MedicineNishinomiyaJapan
  2. 2.Department of Urology, Kidney Transplant CenterHyogo College of MedicineNishinomiyaJapan
  3. 3.Department of RadiologyHyogo College of MedicineNishinomiyaJapan

Personalised recommendations